Corvus Pharmaceuticals to Present at Major Investment Conference
BURLINGAME, Calif. — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a prominent name in the clinical-stage biopharmaceutical sector, is thrilled to announce that its president and CEO, Richard A. Miller, M.D., along with Jeffrey Arcara, the chief business officer, will be participating in one-on-one meetings with investors and delivering a detailed corporate presentation. This important event is set to occur at the H.C. Wainwright 26th Annual Global Investment Conference in New York from September 9 to 11, 2024.
Details of the Event and Presentation Highlights
The key highlight of the event will be Corvus Pharmaceuticals' presentation, which is scheduled for Tuesday, September 10 at 12:00 PM ET. Investors and stakeholders will have the chance to gain valuable insights into the company’s strategic vision and its innovative therapies.
Webcast Information
For those who cannot attend in person, a live webcast of the presentation will be available. Moreover, it will remain accessible for 90 days after the conference, allowing interested individuals to catch up on the discussions and insights shared during the event.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is committed to leading the way in the development of ITK (Interleukin-2-inducible T-cell kinase) inhibition, paving a new path in immunotherapy for various cancers and immune-related conditions. The company’s lead candidate, soquelitinib, is an oral, investigational small molecule drug designed to selectively inhibit ITK. This groundbreaking innovation has the potential to transform treatment approaches for some significant health challenges.
Current Clinical Developments
In addition to soquelitinib, Corvus Pharmaceuticals is actively working on a portfolio of other clinical-stage candidates aimed at addressing different types of cancer. Their dedication to meeting unmet needs in the therapeutic landscape highlights their role as a leader in pioneering treatments.
Investor and Media Contact Information
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
Phone: +1-650-900-4522
Email: llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
Phone: +1-949-903-4750
Email: sseapy@realchemistry.com
Frequently Asked Questions
1. Why is the H.C. Wainwright conference important for Corvus Pharmaceuticals?
The conference serves as a crucial opportunity for Corvus to engage with investors and provide updates on their innovative therapeutic strategies in oncology.
2. Who will represent Corvus Pharmaceuticals at the conference?
Richard A. Miller, M.D., the president and CEO, along with Jeffrey Arcara, Chief Business Officer, will be representing the company.
3. What can attendees expect from the conference presentation?
The presentation is designed to offer insights into the company's strategies, product pipeline, and future directions in cancer treatment.
4. How can individuals access the presentation if they are unable to attend?
A live webcast of the presentation will be available on the Corvus website, and a recording will be accessible for 90 days after the event.
5. What is the primary focus of Corvus Pharmaceuticals?
Corvus is focused on developing innovative therapies that target ITK inhibition to address a wide range of cancer and immune diseases.